Table 9Risk of fracture for pamidronate, any dose, relative to placebo, by fracture group*

Author, yearStudy durationType of fractureRisk levelNumber of fractures, pamidronateNumber of fractures, placebo or control†Odds ratio (95% CI)
VERTEBRAL
Aris, 2000111 24 monthsVertebralHigh3/161/18†3.43 (0.44, 26.92)
Coco, 2003114 12 monthsVertebralHigh1/312/28†0.45 (0.04, 4.52)
Kananen, 2005113 12 monthsVertebralHigh3/335/33†0.57 (0.13, 2.48)
Kim, 2004109 12 monthsvertebralHigh1/256/20†0.14 (0.03, 0.72)
Ninkovic, 2002110 12 monthsvertebralHigh3/341/413.48 (0.47, 25.98)
Reid, 1994112 24 monthsvertebralHigh7/2610/220.45 (0.14, 1.46)
NONVERTEBRAL
Aris, 2000111 24 monthslong bone fractureHigh3/166/18†0.48 (0.11, 2.17)
Ninkovic, 2002110 12 monthsnonvertebralHigh1/341/411.21 (0.07, 19.96)
HIP
Coco, 2003114 12 monthship fracturesHigh0/310/28†NC
*

High-risk: 1) transplant population, or 2) study entry criteria require T score ≤-2.5, or 3) study entry criteria require≥1 fracture, or 4) ≥ 50% population has 1 or more fractures at baseline or 5) Significant neuromuscular impairment. Intermediate-risk: 1) study entry criteria require T score ≤1.5, or 2) 10–50% of population has one or more fracture at baseline, or 3) study population has chronic disease that is commonly treated with glucocorticoids or 4) in the absence of data on BMD or fractures, mean age of population > 62 years. Low-risk: 1) study entry criteria require T score ≤0.0, or 2) < 10% of population has BMD =8 g/cm2 at baseline, or 3) 0–10% of population has one or more fracture at baseline, or in the absence of data on BMD or fracture, mean age of population <62 years. Unknown risk: BMD, fracture history and age not reported as entry criteria or in baseline characteristics of population.

Control group.

From: 3, Results

Cover of Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis
Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis [Internet].
Comparative Effectiveness Reviews, No. 12.
MacLean C, Alexander A, Carter J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.